Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Authors: Jean-Louis Pujol, MD, PhD, Johan Vansteenkiste, MD, PhD, Luis Paz-Ares Rodríguez, MD, PhD, Vanesa Gregorc, MD, Julien Mazieres, MD, PhD, Mark Awad, MD, PhD, Pasi A. Jänne, MD, PhD, Michael Chisamore, PhD, Anwar M. Hossain, MStat, Yanyun Chen, PhD, J. Thaddeus Beck, MD, FACP

Source: JTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100234- (2021)

Subject Terms: Abemaciclib, KRAS-mutant, PD-L1 positive non–small cell lung cancer, Pembrolizumab, Squamous, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S266636432100093X; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/c9caff189596499fa7e9767a030f2c97

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study

Authors: Leou Ismael Banla, MD, PhD, Alice Tzeng, MD, PhD, John P. Baillieul, Melin J. Kandekhar, MD, PhD, Kelly J. Fitzgerald, MD, PhD, Jaclyn LoPiccolo, MD, PhD, Holly A. Poitras, Daniel E. Soto, MD, Julia K. Rotow, MD, Lisa Singer, MD, PhD, Henning Willers, MD, David E. Kozono, MD, PhD, Pasi A. Janne, MD, PhD, Raymond H. Mak, MD, Zofia Piotrowska, MD, Florence K. Keane, MD, Benjamin H. Kann, MD

Source: JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100559- (2023)

Subject Terms: Pneumonitis, Osimertinib, Radiation, Lung cancer, Tyrosine kinase inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364323001029; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/9087b5cf562e48d1adfa693c2233ecf6